Semin Thromb Hemost 2019; 45(01): 121-122
DOI: 10.1055/s-0038-1625972
Erratum
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Erratum: Quebec Platelet Disorder: Update on Pathogenesis, Diagnosis, and Treatment

Catherine P.M. Hayward
1  Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
,
Georges E. Rivard
2  Service d'Hématologie-Oncologie, CHU Sainte-Justine, Montréal, Québec, Canada
› Author Affiliations
Further Information

Address for correspondence

Catherine P.M. Hayward, MD, PhD, FRCP(C)
Department of Pathology and Molecular Medicine, McMaster University
2N29A, 1200 Main St. W., Hamilton, Ontario, L8N 3Z5
Canada   

Publication History

Publication Date:
14 January 2019 (eFirst)

 

The publisher has been informed that there were errors in [Table 1] in the above article in Seminars in Thrombosis and Hemostasis, Volume 37, Number 6, 2011 (DOI: 10.1055/s-0031-1291382).

Table 1

Laboratory findings in Quebec platelet disorder

Laboratory test

Finding

Platelet count

Reduced or normal (80–245 × 109/L)

Other blood counts

Normal unless iron deficient

Platelet Function Analyzer-100® closure times

Normal

Bleeding time

Normal to mildly prolonged

Coagulation and fibrinolysis parameters

PT (INR)

Normal

aPTT

Normal

Fibrinogen

Normal

D-dimer

Normal

uPA

Normal in plasma prepared with platelet activation inhibitors

Elevated in platelets (∼400–600 ng uPA/109 platelets)

uPA-plasminogen activator inhibitor 1 complexes

Normal in plasma

Elevated in platelets

Plasmin- α2 plasmin inhibitor complexes

Normal in plasma

Elevated in platelets

Thromboelastography

(whole blood or platelet rich plasma)

Normal

Light transmission platelet aggregometry

Non-diagnostic findings

Epinephrine

Absent primary or absent secondary aggregation

Adenosine diphosphate

Normal to reduced

Collagen

Normal to reduced

Arachidonic acid

Normal

Thromboxane analogue U46619

Normal

Ristocetin

Normal

Platelet glycoprotein analysis

Western blot analysis for α-granule protein degradation and platelet uPA

α-granule protein degradation and increased platelet uPA

Plasma thrombopoietin levels

<31.3 pg/mL (reference interval: <31.3 pg/mL – 196 pg/mL)

Genetic tests for the QPD PLAU duplication mutation

Positive (duplicated and normal alleles detected)

Abbreviations: ADP, adenosine diphosphate; aPTT, activated partial thromboplastin time; PT (INR), prothrombin time (international normalized ratio); QPD, Quebec platelet disorder; uPA, urokinase plasminogen activator.


Note: The only correction in this table, as compared with the previous version, relates to plasma thrombopoietin levels. All other information is as per previously published. The entire table is provided here for completeness and ease of referral.


The plasma thrombopoietin (TPO) values and TPO assay reference interval that the authors were provided were incorrect. They apologize for not catching these errors before publication. Plasma TPO levels (determined with new samples and the same assay) are actually <31.3 pg/ml in QPD and most general population control samples.[1] A new version of [Table 1], with the correct information,[1] is included in this erratum. No other information in the authors' review requires correction.


#

No conflict of interest has been declared by the author(s).


Address for correspondence

Catherine P.M. Hayward, MD, PhD, FRCP(C)
Department of Pathology and Molecular Medicine, McMaster University
2N29A, 1200 Main St. W., Hamilton, Ontario, L8N 3Z5
Canada